Astrazeneca (AZN) Operating Expenses (2016 - 2026)

Astrazeneca has reported Operating Expenses over the past 16 years, most recently at -$8.4 billion for Q1 2026.

For Q1 2026, Operating Expenses fell 9.95% year-over-year to -$8.4 billion; the TTM value through Mar 2026 reached -$34.9 billion, down 2.93%, while the annual FY2025 figure was $34.2 billion, 1.8% up from the prior year.
Operating Expenses for Q1 2026 was -$8.4 billion at Astrazeneca, up from -$9.4 billion in the prior quarter.
Over five years, Operating Expenses peaked at -$6.7 billion in Q1 2023 and troughed at -$10.1 billion in Q4 2024.
A 5-year average of -$7.9 billion and a median of -$7.7 billion in 2023 define the central range for Operating Expenses.
On a YoY basis, Operating Expenses climbed as much as 12.53% in 2022 and fell as far as 93.53% in 2022.
Year by year, Operating Expenses stood at -$7.2 billion in 2022, then fell by 16.53% to -$8.4 billion in 2023, then fell by 19.46% to -$10.1 billion in 2024, then increased by 7.27% to -$9.4 billion in 2025, then rose by 10.07% to -$8.4 billion in 2026.
Business Quant data shows Operating Expenses for AZN at -$8.4 billion in Q1 2026, -$9.4 billion in Q4 2025, and -$8.7 billion in Q3 2025.

Peer Comparison